Survival outcomes for metastatic castration sensitive prostate cancer: Real world data from a Danish cohort 2016-2022.

Ahmed H. Zedan Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark info_outline Ahmed H. Zedan, Torben Hansen, Signe Timm

Authors Ahmed H. Zedan Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark info_outline Ahmed H. Zedan, Torben Hansen, Signe Timm Organizations Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark Abstract Disclosures Research Funding No funding sources reported Background: Metastatic castration sensitive prostate cancer (mCSPC) has the worst prognosis in the whole disease spectrum of prostate cancers. However, the therapeutic armamentarium has dramatically evolved during the last decade leading to a marked improvement in survival outcomes for this population. The main aim of this study is to investigate the impact of treatment options for mCSPC derived from real world data (RWD). Methods: This is a single retrospective observational study performed at Department of Oncology, Vejle Hospital, Denmark. Eligible patients (men aged ≥18 years) had newly diagnosed, histologically confirmed mCSPC, and were treated with androgen deprivation therapy (ADT) plus either docetaxel (DOC) or novel androgen receptor axis-targeted agents (ARATA) such as abiraterone (ABI) or enzalutamide (ENZ). Endpoints included overall survival (OS), both Radiological- and Biochemical progression free survival (rPFS and bPFS) and time to next treatment (TTNT). Subgroup analysis was done for those whose inclusion criteria were matching to those in the randomized controlled trails (RCTs); both CHAARTED and LATITUDE. Results: In total, 259 patients diagnosed with mCSPC from January 2016 until January 2022 have been included in the study. Patients treated with DOC were 224 (87%), while ABI and ENZ were used in 32 (12%), and 3 (1%) patients, respectively. Data analysis was done after a median follow-up of 39.9 months (range 11.4-85.1). Median OS, rPFS and bPFS were not reached during the follow-up period, while median TTNT was 26.7 months (95% CI 23.8-31.2). For the above defined subgroup (233 patients) median TTNT was 26.2 months (95% CI 23.2-29.7). Conclusions: Observations from this study emphasizes the remarkable benefits for treatment intensification for mCSPC population, and inclusion of RWD resulted in outcomes comparable with RCTs.